CD38-SADA

N/A

Report date: 2025/01/26 19:36:30

Base Information

Drug NameCD38-SADA
Drug Alias NameRadioimmunotherapy (Y-mAbs Therapeutics Inc)CD38-SADA
ClassificationBiologics
Mechanisms of ActionLymphocyte differentiation antigen CD38 modulators
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesY-Mabs Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesY-Mabs Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, Non-Hodgkin
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A